Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44‐Targeted Hydrogel Nanobot
Schematic illustration of the preparation of a HER2/CD44-targeted hydrogel nanobot (ALPR) by embedding the positively charged bio-responsive, liposome-encapsulated nanoparticles (LPR) formed by cationic liposome DOTAP/DOPE, survivin siRNA, andD-(KLAKLAK)2GGR16 (KLA-R16) into negatively charged Herceptin/hyaluronic acid cross-linked nanohydrogels (Herceptin-HA). AbstractHeterogeneity and drug resistance of tumor cells are the leading causes of incurability and poor survival for patients with recurrent breast cancer. In order to accurately deliver the biological anticancer drugs to different subtypes of malignant tumor cells for omnidirectional targeted treatment of recurrent breast cancer, a distinct design is demonstrated by embedding liposome-based nanocomplexes containing pro-apoptotic peptide and survivin siRNA drugs (LPR) into Herceptin/hyaluronic acid cross-linked nanohydrogels (Herceptin-HA) to fabricate a HER2/CD44-targeted hydrogel nanobot (named as ALPR). ALPR delivered cargoes to the cells overexpressing CD44 and HER2, followed by Herceptin-HA biodegradation, subsequently, the exposed lipid component containing DOPE fused with the endosomal membrane and released peptide and siRNA into the cytoplasm. These experiments indicated that ALPR can specifically deliver Herceptin, peptide, and siRNA drugs to HER2-positive SKBR-3, triple-negative MDA-MB-231, and HER2-negative drug-resistant MCF-7 human breast cancer cells. ALPR completely inhibited the growth of heterogeneous...
Source: Small - Category: Nanotechnology Authors: Juan Chen,
Jinjin Li,
Xiaolu Sun,
Huixia Lu,
Kuai Liu,
Zhenbo Li,
Jianyue Guan,
Huiling Song,
Wei Wei,
Yanhong Ge,
Qiong Fan,
Wei Bao,
Buyong Ma,
Zixiu Du Tags: Research Article Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemistry | Genetics | HER2 | Herceptin | Mitochondria | Nanotechnology